Psoriatic Arthritis – Landscape & Forecast – Disease Landscape & Forecast
The psoriatic arthritis (PsA) therapy market has become increasingly dynamic with the recent launches of several targeted agents—Janssen’s Tremfya and AbbVie’s Rinvoq and Skyrizi. Furthermore, a series of approvals expected in the next decade will likely present an increasing challenge to the dominance of the TNF inhibitors, especially as biosimilars are increasingly accepted as alternatives to more-expensive branded therapies and drugs with novel mechanisms of action become available. Interleukin (IL)-17 and IL-23 inhibitors, in particular, are poised to capture substantial sales and, with the diagnosis and drug-treatment rate anticipated to remain relatively steady, could threaten the positions of current market leaders. The impending entry of the first TYK2 inhibitor (BMS’s deucravacitinib), an additional IL-17 inhibitor (UCB’s bimekizumab), and an IL-23 inhibitor (Sun Pharma’s tildrakizumab) will also create interesting market dynamics.
Questions answered
- What impact will current and emerging biosimilars have on the PsA therapy market in the coming years? How will physicians in different markets react to these less expensive therapies?
- How will newer agents, especially those offering an alternative to the market-leading TNF inhibitors, change the PsA therapy market? What is the physician perception of these therapies?
- What emerging therapies do dermatologists and rheumatologists consider the most promising for PsA? What novel mechanisms of action are considered good clinical targets for this disease?
- What unmet needs remain in the treatment of PsA? Will emerging therapies fulfill these needs, and will they be competitive with biosimilars and entrenched branded therapies?
Content highlights:
Geographies: United States, EU5, Japan.
Primary research: Approximately 20 country-specific interviews with thought-leading dermatologists and rheumatologists supported by survey data collected for this and other Clarivate research.
Epidemiology: Number of PsA patients by country, including diagnosed and drug-treated populations.
Forecast: 10-year, annualized, drug-level sales and patient share of key PsA therapies to 2031, segmented by brands / generics.
Emerging therapies: Phase III/PR: 3 drugs; Phase II: 3 drugs.
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution enhancement
Disease Landscape & Forecast will feature continual updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.
Additionally, Disease Landscape & Forecast introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
Table of contents
- Psoriatic Arthritis - Landscape & Forecast - Disease Landscape & Forecast
- Key findings
- Key updates
- Q4 2022
- December 2022
- October 2022
- Q3 2022
- September 2022
- August 2022
- July 2022
- Q2 2022
- June 2022
- May 2022
- April 2022
- Q1 2022
- March 2022
- February 2022
- January 2022
- Q4 2022
- Market outlook
- Key findings
- Market share of drug classes for PsA: 2021
- Market share of drug classes for PsA: 2031
- PsA SWOT analysis
- Market drivers and constraints
- What factors are driving the market for PsA?
- What factors are constraining the market for PsA?
- Annual sales of TNF inhibitors in PsA: 2021-2031
- Annual sales of select drugs in PsA: 2021-2031
- Drug-class-specific trends
- U.S. patient share for TNF inhibitors in PsA: 2021-2031
- EU5 patient share for TNF inhibitors in PsA: 2021-2031
- Japanese patient share for TNF inhibitors in PsA: 2021-2031
- Major-market brand and biosimilar sales of ustekinumab in PsA: 2021-2031
- Patient share of ustekinumab for PsA in the United States, EU5, and Japan: 2021-2031
- Major-market sales of IL-17 inhibitors for PsA: 2021-2031
- Major-market patient share of IL-17 inhibitors in PsA: 2021-2031
- Major-market sales and patient share of IL-23 inhibitors in PsA: 2021-2031
- Sales of apremilast for PsA in the United States, EU5, and Japan: 2021-2031
- Major-market patient share and sales of JAK inhibitors in PsA: 2021-2031
- Major-market patient share of PDE4, JAK, and TYK2 inhibitors in PsA: 2021-2031
- Sales of abatacept for PsA in the United States and EU5: 2021-2031
- Key findings
- Forecast
- Market forecast assumptions
- Market forecast dashboard
- Etiology and pathophysiology
- Disease overview
- Etiology
- Risk factors for PsA
- Pathophysiology
- Clinical, extra-articular, and radiographic features of various spondyloarthropathies
- Pathogenesis
- Pathological changes in early and late PsA
- Key pathways and drug targets
- Pathogenesis and drug targets
- Disease overview
- Epidemiology
- Key findings
- Epidemiology populations
- Disease definition, methods, and sources used
- Total prevalent cases of psoriatic arthritis: 2021-2031 (thousands)
- Sources used for diagnosed prevalence of psoriatic arthritis
- Diagnosed prevalent cases of psoriatic arthritis: 2021-2031 (thousands)
- Sources used for diagnosed drug-treated prevalence of psoriatic arthritis
- Diagnosed drug-treated prevalent cases of psoriatic arthritis: 2021-2031 (thousands)
- Key findings
- Current treatment
- Key findings
- Treatment goals
- Key endpoints used in clinical trials for PsA
- Key current therapies
- Overview
- Mechanism of action of key current drug classes used for PsA
- Current treatments used for PsA
- Market events impacting the use of key current therapies in PsA
- Advantages and disadvantages of TNF-u03b1 inhibitors
- Expert insight: TNF inhibitors
- Advantages and disadvantages of ustekinumab
- Ongoing clinical development
- Expert insight: ustekinumab
- Advantages and disadvantages of secukinumab
- Ongoing clinical development
- Expert insight: secukinumab
- Advantages and disadvantages of brodalumab
- Advantages and disadvantages of ixekizumab
- Advantages and disadvantages of guselkumab
- Ongoing clinical development
- Expert insight: guselkumab
- Risankizumab
- Advantages and disadvantages of risankizumab
- Expert insight: risankizumab
- Advantages and disadvantages of tofacitinib
- Expert insight: tofacitinib
- Upadacitinib
- Advantages and disadvantages of upadacitinib
- Expert insight: upadacitinib
- Advantages and disadvantages of apremilast
- Ongoing clinical development
- Expert insight: apremilast
- Advantages and disadvantages of abatacept
- Expert insight: abatacept
- Advantages and disadvantages of cDMARDs
- Expert insight: cDMARDs
- Medical practice
- Overview
- Factors influencing drug selection in PsA
- Treatment decision tree for PsA: United States
- Treatment decision tree for PsA: Europe
- Treatment decision tree for PsA: Japan
- Key findings
- Unmet need overview
- Current and future attainment of unmet needs in PsA
- Top unmet needs in PsA: current and future attainment
- Expert insight: unmet need in PsA
- Drug pipeline
- Pipeline
- Regulatory Milestones
- Indication Comparison
- Emerging therapies
- Key findings
- Key emerging therapies
- Key emerging therapies in development for PsA
- Estimated launch dates of key emerging therapies for the treatment of PsA
- Bimekizumab profile
- Key ongoing clinical trials of bimekizumab in the treatment of PsA
- Analysis of the clinical development program for bimekizumab
- Expert insight: bimekizumab
- Expectations for launch and sales opportunity of bimekizumab in psoriatic arthritis
- Tildrakizumab profile
- Key ongoing clinical trials of tildrakizumab in the treatment of PsA
- Analysis of the clinical development program for tildrakizumab
- Expert insight: tildrakizumab
- Expectations for launch and sales opportunity of tildrakizumab in PsA
- Deucravacitinib profile
- Key ongoing clinical trials of deucravacitinib in the treatment of psoriatic arthritis
- Analysis of the clinical development program for deucravacitinib
- Expert insight: deucravacitinib
- Expectations for launch and sales opportunity of deucravacitinib in psoriatic arthritis
- Early-phase pipeline analysis
- Select compounds in early-phase development for PsA
- Key findings
- Access and reimbursement overview
- Region-specific reimbursement practices
- General reimbursement environment: United States
- General reimbursement environment: EU5
- General reimbursement environment: Japan
- Region-specific reimbursement practices
- Appendix
- Abbreviations
- Bibliography
- Key findings
Swati Kinger, M.B.A., Healthcare Research & Data Analyst, Immune and Inflammation. Ms. Kinger’s focus is the axial spondyloarthritis market. Previously, she was an associate consultant for a life sciences firm, where she worked on syndicated offerings and ad-hoc requests involving patient journeys, market assessment, and competitive intelligence. She holds a bachelor’s degree in pharmacy from Delhi University and an M.B.A. in pharmacy from the National Institute of Pharmaceutical Education and Research in India.
Rohit Rout, M.Pharm., Research Associate, Immune and Inflammation. Mr. Rout joined as an intern on the China-In-Depth team at Clarivate, where he performed secondary market research for China’s biopharmaceutical market. Before joining Clarivate, he was an associate scientist in the biopharmaceutics (IVIVC) department at Lupin Pvt. Ltd. He holds an M.Pharm. degree in pharmaceutics from the Birla Institute of Technology and Science in Pilani, India.